European Journal of Dermatology
MENUSclerodermiform porphyria cutanea tarda after torasemide Volume 25, numéro 5, September-October 2015
Illustrations
Medical University Graz,
Department of Dermatology,
Auenbruggerplatz 8, 8036 Graz, Austria
Department of Dermatology,
Auenbruggerplatz 8, 8036 Graz, Austria
- DOI : 10.1684/ejd.2015.2556
- Page(s) : 484-5
- Année de parution : 2015
Porphyria cutanea tarda (PCT), a late onset hepatic porphyria, develops when the activity of uroporphyrinogen decarboxylase (Uro-D) is decreased. The acquired type, induced by liver disease or drugs, is common. Typical cutaneous symptoms include skin fragility, vesicles, bullous lesions, atrophic scars, facial hypertrichosis, hyperpigmentation and scarring alopecia [1]. Pseudoscleroderma occurs in 15-18% of patients with an underlying liver disease or in patients on maintenance hemodialysis [2, 3]. [...]